WHO ICTRP trial
Alendronate in ankylosing spondylitis trial
ISRCTN12308164 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN12308164 |
|---|---|
| Public title | Alendronate in ankylosing spondylitis trial |
| Scientific title | Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial |
| Primary sponsor | Royal National Hospital for Rheumatic Diseases (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | United Kingdom |
| Conditions | Ankylosing spondylitis Musculoskeletal Diseases Ankylosing spondylitis |
| Interventions | Oral alendronate 70 mg weekly or placebo The total duration of treatment was 2 years and follow-up for all treatment arms was 2 years from enrolment. |
| Registration date | Dec 15, 2015 |
| Target size | 180 |
| Secondary IDs | BSR / Arthritis Research UK project grant (14585) |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: